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Background: The metastasis-associated gene 1 (MTA1) has been identified as one critical regulator of tumor
metastasis. Previously, we identified miR-125b as a downregualted miRNA in non-small cell lung cancer (NSCLC) cell
line upon MTA1 depletion. However, the role of miR-125b and MTA1 in the regulation of NSCLC metastasis remains
unclear.
Methods: Stable MTA1 knockdown NSCLC cell lines 95D and SPC-A-1 were established by transfection with MTA1
shRNA. The effects of MTA1 depletion on the expression of miR-125b and cell migration and invasion were
examined by real-time PCR, wound healing and matrigel invasion assay.
Results: MTA1 knockdown led to the upregulation of miR-125b level in NSCLC cells. Furthermore, MTA1
knockdown reduced while miR-125b inhibitor enhanced cell migration and invasion of NSCLC cells. Notably, miR-
125b inhibitor antagonized MTA1 siRNA induced inhibition of cell migration and invasion.
Conclusion: MTA1 and miR-125b have antagonistic effects on the migration and invasion of NSCLC cells. The
newly identified MTA1-miR-125b axis will help further elucidate the molecular mechanism of NSCLC progression
and suggest that ectopic expression of miR-125b is a potentially new therapeutic regimen against NSCLC
metastasis.
Keywords: miR-125b, MTA1, Non-small cell lung cancer, MetastasisIntroduction
Metastasis is the leading cause of failure in clinical treat-
ment of malignant tumors including lung cancer. The
metastasis-associated gene 1 (MTA1) has been identified
as one critical regulator of the metastasis of many
human cancers [1-4]. In our previous studies we
deomnstrated that MTA1 promoted the metastasis of
non-small cell lung cancer (NSCLC), and identified miR-
125b as a downregualted miRNA in NSCLC cell line
upon MTA1 depletion [5,6]. However, the role of miR-* Correspondence: zhuxx011@163.com; whf0001@163.com
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reproduction in any medium, provided the or125b and MTA1 in the regulation of invasive phenotype
of NSCLC cells remains unclear.
It has been shown that miR-125b level was signifi-
cantly correlated with good prognosis of liver cancer [7].
miR-125b was deregulated in lung cancer, oral squamous
cell carcinoma, prostate cancer and pancreatic cancer
[8-11]. However, controversial properties of miR-125b
have been reported in different types of cancer. In hu-
man invasive breast cancer, miR-125b functioned as a
tumor suppressor by regulating ETS1 proto-oncogene
[12]. In addition, miR-125b was underexpressed in meta-
static hepatocellular carcinoma (HCC) and inhibited
HCC cell migration and invasion by directly targeting
oncogene LIN28B2 [13,14]. In contrast, exogenous miR-
125b expression increased the migration of type I endo-
metrial carcinoma cell line [15]. Moreover, miR-125b
was proposed to function as a metastasis promoterhis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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These data suggest that miR-125b may perform different
regulatory functions on tumor progression in a cellular
context-dependent manner.
In the present study, we established two MTA1-
knockdown NSCLC cell lines using stable transfection
technology and validated the effects of MTA1 depletion
on the expression of miR-125b. Using these cell lines we
further examined the function of miR-125b in the
regulatuion of cell migration and the interaction be-
tween miR-125b and MTA1. Our resutls showed that
miR-125b acted as a metastasis suppressor in vitro and
reversed the stimulatous effect of MTA1 on the migra-
tion of NSCLC cell lines.
Methods
Cell culture
Human non-small lung cancer cell lines 95D and SPC-A-1
were purchased from Shanghai Cell Bank of Chinese
Academy of Science (Shanghai, China). Cells were cul-
tured in RPMI 1640 medium (Invitrogen, Carlsbad,
CA) supplemented with 10% fetal calf serum at 37°C in
a humidified atmosphere containing 5% CO2.
Transient transfection
miR-125b-inhibitor (5′-UCACAAGUUAGGGUCUCAG
GGA-3′) and nonspecific control miRNA (NC, 5′-CAG
UACUUUUGUGUAGUACAA-3′) were designed based
on miRbase Database (www.miRbase.org) and synthesized
by Genepharma (Shanghai, China). Cells were seeded
(1.6×104/well) onto 96-well plate 18–20 h before transfec-
tion. Anti-miR-125b or NC was added to each well. After
6 h incubation at 37°C and 5% CO2, the medium was re-
placed with fresh culture medium. The cells were
harvested at 48 h post transfection.
Establishment of stable cell line
Cells were transfected with 3 μg of plasmids (pLVTHM-
MTA1-si, or pLVTHM-CTL-si) which were constructed
in previous study [6], or empty pLVTHM vector using
Lipofectamine2000 (Invitrogen, Carlsbad, CA) according
to the manufacturer’s protocol, then selected for the re-
sistant to neomycin. The stable resistant cell lines were
selected and named as 95D (or SPC-A-1)/MTA1-si, 95D
(or SPC-A-1)/ CTL-si, and 95D (or SPC-A-1)/NC,
respectively.
Quantitative real-time PCR
Total RNA was extracted from the cells with Trizol re-
agent (Invitrogen) following the manufacturer’s instruc-
tion. Quantitative real-time PCR for miR-125b or MTA1
mRNA was performed as described previously [6]. For
miR-125b quantification, U6 small nuclear RNA (U6
snRNA) was used as internal control. The primerssequences were as follows: hsa-miR-125b forward:
GGCAACCTTGCGACTATAACCA, reverse: GTTTCCT
CTCCCTGAGACCCTA; U6 snRNA forward: CTCGCTT
CGGCAGCACATATACT, reverse ACGCTTCACGAAT
TTGCGTGTC. The relative quantification of expression
levels was calculated using the 2−ΔΔCt method.Western blot analysis
Total protein was extracted from the cells using RIPA
kit (Pierce, USA). Protein concentrations of the superna-
tants were determined using BCA method. Equal
amounts of proteins were separated by SDS-PAGE and
transferred into nitrocellulose membranes, which were
incubated with primary antibodies against MTA1
(1:1500; Abcam, Cambridge, MA, USA) and β-Actin
(1:1000; Santa Cruz Biotech, Santa Cruz, CA, USA) at
4°C overnight. The membranes were washed three
times with TBST and incubated with peroxidase conju-
gated goat anti-rabbit IgG secondary antibody (1:1000,
Santa Cruz Biotech, Santa Cruz, CA, USA) for 1 h at
room temperature. Finally, the membranes were washed
three times with TBST and visualized using Western Blot-
ting Luminol Reagent (Santa Cruz Biotech, Santa Cruz,
CA, USA) according to the manufacturer’s instruction.Wound healing assay
Cells were seeded into six-well plate and grown to con-
fluence. Wound was created by scraping confluent cell
monolayers with a pipette tip. The cells were allowed to
migrate for 48 h. At 0 h and 48 h after scratching, im-
ages were taken under the inverted microscope to assess
the ability of the cells to migrate into the wound area.Cell invasion assay
5×104 cells in serum-free media were seeded into the
upper chambers of a 24-well BioCoat Matrigel invasion
chamber (BD Bioscience, Bedford, MA, USA). Medium
with 10% FBS was added to the lower chambers as a
chemoattractant. After 24 h of incubation, cells that in-
vaded through the membrane filter were fixed and
stained with H&E. The number of invading cells was
counted under fluorescence microscope in five random
high power fields.Statistical analysis
All experiments were repeated independently a mini-
mum of three times, and the results were expressed as
the mean values ± standard deviation. The differences
between groups were analyzed by two-tailed unpaired
Student’s t test. A value of p < 0.05 was considered to in-
dicate statistical significance.
Figure 1 MTA1 knockdown leads to the upregulation of miR-125b level in NSCLC cells. A. Quantification of MTA1 mRNA level by
quantitative RT-PCR in 95D and SPC-A-1 cells untransfected, transfected with MTA1 shRNA or control shRNA. B. Western blot analysis of MTA1 protein
level in 95D and SPC-A-1 cells untransfected, transfected with MTA1 shRNA or control shRNA. B-actin was loading control. C. Quantification of miR-
125b level by quantitative RT-PCR in 95D and SPC-A-1 cells transfected with MTA1 shRNA or control shRNA. D. Quantification of miR-125b level by
quantitative RT-PCR in 95D and SPC-A-1 cells transfected with MTA1 shRNA or control shRNA, together with miR-125b inhibitor or control. *P < 0.05,
**P < 0.01 compared to the controls.
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MTA1 knockdown leads to the upregulation of miR-125b
level in NSCLC cells
First we established 95D and SPC-A-1 cell lines with
stable knockdown of MTA1 by transfecting the cells
with MTA1 shRNA. The knockdown efficiency was con-
firmed by qRT-PCR and Western blot analysis.Figure 2 MTA1 and miR-125b have antagonistic effects on the migrat
cells transfected with MTA1 shRNA or control shRNA, together with miR-12
calculated as (the width of wound at 0 h - the width of wound at 36 h)/ th
healing assay on the migration of SPC-A-1 cells transfected with MTA1 shR
percentage of the wound healing was calculated as (the width of wound a
*P < 0.05, **P < 0.01 compared to controls.Compared to the control cell lines, the expression of
MTA1 mRNA and protein was significantly reduced in
95D and SPC-A-1 cells transfected with pLVTHM-
MTA1-si plasmid (Figure 1A, B).
Next we detected miR-125b level in the established
cell lines. The results showed that miR-125b level was
2.75 and 1.67-fold higher in 95D/MTA1-si and SPC-ion of NSCLC cells. A. Wound healing assay on the migration of 95D
5b inhibitor or control. The percentage of the wound healing was
e width of wound at 0 h. **P < 0.01 compared to controls. B. Wound
NA or control shRNA, together with miR-125b inhibitor or control. The
t 0 h - the width of wound at 48 h)/ the width of wound at 0 h.
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SPC-A-1 cells, respectively (Figure 1C). To confirm the
negative correlation between MTA1 and miR-125b in
NSCLC cells, we transfected miR-125b-inhibitor or
nonspecific control miRNA (NC) into 95D and SPC-A-1
cells. qRT-PCR analysis showed that miR-125b-inhibitor
decreased the expression of miR-125b in 95D/CTL-si
and SPC-A-1/CTL-si cells only by 30 percent, but it
significantly reduced miR-125b expression in 95D/MTA1-
si and SPC-A-1/MTA1-si cells (Figure 1D). These data
suggest that MTA1 knockdown leads to the upregulation
of miR-125b level in NSCLC cells.
MTA1 and miR-125b have antagonistic effects on the
migration and invasion of NSCLC cells
Next we investigated the antagonistic effects of MTA1
and MiR-125b on the migration and invasion of NSCLC
cells. Wound healing assay showed that in 95D cells,
knockdown of MTA1 led to reduced cell migration.
However, cell migration was increased in 95D cells
treated with miR-125b inhibitor. Moreover, the migra-
tion of cells treated with both MTA1 shRNA and miR-
125b inhibitor was similar to control cells (Figure 2A).Figure 3 MTA1 and miR-125b have antagonistic effects on the invasio
cells transfected with MTA1 shRNA or control shRNA, together with miR-12
random fields at 40x magnification. *P < 0.05, **P < 0.01 compared to contr
transfected with MTA1 shRNA or control shRNA, together with miR-125b in
fields at 40x magnification. **P < 0.01 compared to controls.Similar results were observed for the migration of SPC-
A-1 cells (Figure 2B). These data demonstrate that
MTA1 promotes while miR-125b inhibits NSCLC cell
migration and indicate that MTA1 may promote cell mi-
gration via the downregulation of miR-125b.
Matrigel invasion assay showed that in 95D cells,
knockdown of MTA1 led to reduced cell invasion. How-
ever, cell invasion was increased in 95D cells treated
with miR-125b inhibitor. Moreover, the invasion of cells
treated with both MTA1 shRNA and miR-125b inhibitor
was similar to control cells (Figure 3A). Similar results were
observed for the invasion of SPC-A-1 cells (Figure 3B).
These data demonstrate that MTA1 promotes while
miR-125b inhibits NSCLC cell invasion and indicate
that MTA1 may promote cell invasion via the
downregulation of miR-125b.
Discussion
Recent studies have demonstrated the crucial role of
miR-125b in tumorigenesis and metastasis [17-20].
Nevertheless, the role of miR-125b in lung cancer re-
mains controversial. chr11q23-24 and chr21q11-21 are
the region in which miR-125b-1 and miR-125b-2 aren of NSCLC cells. A. Transwell invasion assay on the invasion of 95D
5b inhibitor or control. The invaded cells were counted from 5
ols. B. Transwell invasion assay on the invasion of SPC-A-1 cells
hibitor or control. The invaded cells were counted from 5 random
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patients with lung cancer, indicating that miR-125b may
function as a tumor suppressor in lung cancer [8,21].
However, miR-125b exhibited higher expression level in
non-responsive patients with cisplatin-based chemother-
apy [22]. Furthermore, the high level of miR-125b was
significantly correlated with poor patient survival
[22,23]. These data suggest that miR-125b may act as an
oncogene in lung cancer.
In the present study, by cell biological analysis we
demonstrated that inhibition of miR-125b promoted the
migration and invasion of NSCLC cells, providing some
evidence that miR-125b could serve as a tumor suppres-
sor in the metastasis of NSCLC in vitro. The upstream
regulators of miR-125b expression remain to be identi-
fied. Recently Liu et al. reported that STAT3 could promote
the transcription of miR-125b in human osteosarcoma cells
[24]. In addition, CDX2, a homeobox transcription factor,
has been recently shown to bind to the promoter region of
miR-125b and activate its transcription in malignant mye-
loid cells [25]. By microarray analysis, we previously found
that miR-125b was significantly upregulated in MTA1
knockdown NSCLC cells [6]. In this study, we verified that
endogenous expression of miR-125b increased after the de-
pletion of MTA1 in two NSCLC cell lines, suggesting that
miR-125b is regulated by MTA1 at the level of transcrip-
tion. Furthermore, we found that the inhibition of miR-
125b could rescue the suppressive effects of MTA1 silen-
cing on NSCLC cell migration and invasion. These results
demonstrate for the first time that miR-125b is a functional
target of MTA1 in lung cancer cells and suggest that ec-
topic expression of miR-125b is a promising strategy to
counteract the promotion of tumor progression by MTA1.
It is known that MTA1, which is an integral part of
nucleosome remodeling and deacetylation (NuRD) com-
plexes, represses the transcription of target genes by
recruiting histone deacetylases onto the promoter re-
gions of target genes and inducing histone deacetylation
[25]. Further studies are needed to elucidate the mech-
anism by which MTA1 downregulates the transcription
of miR-125b in lung cancer cells.
Conclusions
In summary, we found that the expression of MTA1 and
miR-125b is negatively correlated in lung cancer cells
and they have antagonistic effects on the migration and
invasion of NSCLC cells. The newly identified MTA1-
miR-125b axis will help further elucidate the molecular
mechanism of NSCLC progression and suggest that ec-
topic expression of miR-125b is a potentially new thera-
peutic regimen against NSCLC metastasis.
Competing interests
The authors declare that they have no competing interests.Authors’ contributions
YL, YC, YF, JW, MW performed most of the experiments. HW and XZ
designed the study. HZ and MY performed statistical analysis. XZ supervised
the study and wrote the manuscript. All authors read and approved the final
manuscript.
Acknowledgement
This study was supported by grants from National Natural Science
Foundation of China (No. 81001047/H1615), Educational Commission of
Guangdong Province (No. LYM09037), Science and technology projects in
Guangdong Province (No. 2012B031800127), and Natural Science Foundation
of Guangdong Province (No. 9151051501000035).
Received: 10 May 2013 Accepted: 21 May 2013
Published: 29 May 2013
References
1. Jiang Q, Zhang H, Zhang P: ShRNA-mediated gene silencing of MTA1
influenced on protein expression of ER alpha, MMP-9, CyclinD1 and
invasiveness, proliferation in breast cancer cell lines MDA-MB-231 and
MCF-7 in vitro. J Exp Clin Cancer Res 2011, 30:60.
2. Wang H, Fan L, Wei J, Weng Y, Zhou L, Shi Y, Zhou W, Ma D, Wang C: Akt
mediates metastasis-associated gene 1 (MTA1) regulating the expression
of E-cadherin and promoting the invasiveness of prostate cancer cells.
PLoS One 2012, 7(12):e46888.
3. Zhou H, Xu X, Xun Q, Yu D, Ling J, Guo F, Yan Y, Shi J, Hu Y: microRNA-30c
negatively regulates endometrial cancer cells by targeting metastasis-
associated gene-1. Oncol Rep 2012, 27(3):807–812.
4. Marzook H, Li DQ, Nair VS, Mudvari P, Reddy SD, Pakala SB, Santhoshkumar
TR, Pillai MR, Kumar R: Metastasis-associated protein 1 drives tumor cell
migration and invasion through transcriptional repression of RING finger
protein 144A. J Biol Chem 2012, 287(8):5615–5626.
5. Zhu X, Guo Y, Li X, Ding Y, Chen L: Metastasis-Associated Protein 1
Nuclear Expression is Associated with Tumor Progression and Clinical
Outcome in Patients with Non-small Cell Lung Cancer. J Thorac Oncol
2010, 5:1159–1166.
6. Zhu X, Zhang X, Wang H, Song Q, Zhang G, Yang L, Geng J, Li X, Yuan Y,
Chen L: MTA1 gene silencing inhibits invasion and alters the microRNA
expression profile of human lung cancer cells. Oncol Rep 2012,
28:218–224.
7. Li W, Xie L, He X, Li J, Tu K, Wei L, Wu J, Guo Y, Ma X, Zhang P, Pan Z, Hu X,
Zhao Y, Xie H, Jiang G, Chen T, Wang J, Zheng S, Cheng J, Wan D, Yang S,
Li Y, Gu J: Diagnostic and prognostic implications of microRNAs in
human hepatocellular carcinoma. Int J Cancer 2008, 123:1616–1622.
8. Yamada H, Yanagisawa K, Tokumaru S, Taguchi A, Nimura Y, Osada H,
Nagino M, Takahashi T: Detailed characterization of a homozygously
deleted region corresponding to a candidate tumor suppressor locus at
21q11-21 in human lung cancer. Genes Chromosomes Cancer 2008,
47:810–818.
9. Henson BJ, Bhattacharjee S, O’Dee DM, Feingold E, Gollin SM: Decreased
expression of miR-125b and miR-100 in oral cancer cells contributes to
malignancy. Genes Chromosomes Cancer 2009, 48:569–582.
10. Schaefer A, Jung M, Mollenkopf HJ, Wagner I, Stephan C, Jentzmik F, Miller
K, Lein M, Kristiansen G, Jung K: Diagnostic and prognostic implications of
microRNA profiling in prostate carcinoma. Int J Cancer 2010,
126:1166–1176.
11. Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG,
Bhatt D, Taccioli C, Croce CM: MicroRNA expression patterns to
differentiate pancreatic adenocarcinoma from normal pancreas and
chronic pancreatitis. JAMA 2007, 297:1901–1908.
12. Zhang Y, Yan LX, Wu QN, Du ZM, Chen J, Liao DZ, Huang MY, Hou JH, Wu
QL, Zeng MS, Huang WL, Zeng YX, Shao JY: miR-125b is methylated and
functions as a tumor suppressor by regulating the ETS1 proto-oncogene
in human invasive breast cancer. Cancer Res 2011, 71:3552–3562.
13. Budhu A, Jia HL, Forgues M, Liu CG, Goldstein D, Lam A, Zanetti KA, Ye QH,
Qin LX, Croce CM, Tang ZY, Wang XW: Identification of metastasis-related
microRNAs in hepatocellular carcinoma. Hepatology 2008, 47:897–907.
14. Liang L, Wong CM, Ying Q, Fan DN, Huang S, Ding J, Yao J, Yan M, Li J, Yao
M, Ng IO, He X: MicroRNA-125b suppressesed human liver cancer cell
proliferation and metastasis by directly targeting oncogene LIN28B2.
Hepatology 2010, 52:1731–1740.
Li et al. Journal of Experimental & Clinical Cancer Research 2013, 32:33 Page 7 of 7
http://www.jeccr.com/content/32/1/3315. Jiang F, Liu T, He Y, Yan Q, Chen X, Wang H, Wan X: MiR-125b promotes
proliferation and migration of type II endometrial carcinoma cells
through targeting TP53INP1 tumor suppressor in vitro and in vivo.
BMC Cancer 2011, 11:425.
16. Tang F, Zhang R, He Y, Zou M, Guo L, Xi T: MicroRNA-125b induces
metastasis by targeting STARD13 in MCF-7 and MDA-MB-231 breast
cancer cells. PLoS One 2012, 7:e35435.
17. Kappelmann M, Kuphal S, Meister G, Vardimon L, Bosserhoff AK: MicroRNA
miR-125b controls melanoma progression by direct regulation of c-Jun
protein expression. Oncogene 2012. doi:10.1038/onc.2012.307 [Epub ahead
of print].
18. Ngo-Yin Fan D, Ho-Ching Tsang F, Hoi-Kam Tam A, Leung-Kuen Au S,
Chak-Lui Wong C, Wei L, Man-Fong Lee J, He X, Oi-Lin Ng I, Wong CM:
Histone lysine methyltransferase, suppressor of variegation 3–9 homolog
1, promotes hepatocellular carcinoma progression and is negatively
regulated by microRNA-125b. Hepatology 2013, 57(2):637–47.
19. Xu N, Zhang L, Meisgen F, Harada M, Heilborn J, Homey B, Grandér D,
Ståhle M, Sonkoly E, Pivarcsi A: MicroRNA-125b down-regulates matrix
metallopeptidase 13 and inhibits cutaneous squamous cell carcinoma
cell proliferation, migration, and invasion. J Biol Chem 2012,
287(35):29899–908.
20. Liu LH, Li H, Li JP, Zhong H, Zhang HC, Chen J: Xiao T.miR-125b
suppresses the proliferation and migration of osteosarcoma cells
through down-regulation of STAT3. Biochem Biophys Res Commun 2011,
416(1–2):31–8.
21. Martin ES, Cesari R, Pentimalli F, Yoder K, Fishel R, Himelstein AL, Martin SE,
Godwin AK, Negrini M, Croce CM: The BCSC-1 locus at chromosome
11q23-q24 is a candidate tumor suppressor gene. Proc Natl Acad Sci USA
2003, 100(20):11517–22.
22. Cui EH, Li HJ, Hua F, Wang B, Mao W, Feng XR, Li JY, Wang X: Serum
microRNA 125b as a diagnostic or prognostic biomarker for advanced
NSCLC patients receiving cisplatin-based chemotherapy. Acta Pharmacol
Sin 2013, 34(2):309–13.
23. Yuxia M, Zhennan T, Wei Z: Circulating miR-125b is a novel biomarker for
screening non-small-cell lung cancer and predicts poor prognosis.
J Cancer Res Clin Oncol 2012, 138(12):2045–50.
24. Lin KY, Zhang XJ, Feng DD, Zhang H, Zeng CW, Han BW, Zhou AD, Qu LH,
Xu L, Chen YQ: miR-125b, a target of CDX2, regulates cell differentiation
through repression of the core binding factor in hematopoietic
malignancies. J Biol Chem 2011, 286(44):38253–63.
25. Toh Y, Kuninaka S, Endo K, Oshiro T, Ikeda Y, Nakashima H, Baba H, Kohnoe
S, Okamura T, Nicolson GL, Sugimachi K: Molecular analysis of a candidate
metastasis-associated gene, MTA1: possible interaction with histone
deacetylase 1. J Exp Clin Cancer Res 2000, 19:105–11.
doi:10.1186/1756-9966-32-33
Cite this article as: Li et al.: MTA1 promotes the invasion and migration
of non-small cell lung cancer cells by downregulating miR-125b. Journal
of Experimental & Clinical Cancer Research 2013 32:33.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
